VAXIMM AG (Mannheim, Germany) is a clinical-stage biopharmaceutical company dedicated to the development of immunotherapies for patients suffering from cancer. The lead program, VXM01, is an oral T-cell vaccine designed to elicit an immune response against the vascular endothelium growth factor receptor-2 (VEGFR-2). VXM01 is in clinical phase I/II in several oncology indications. VAXIMM is a spin-out from Merck Serono.
Sten Verland, PhD MSc

General Partner

Mobile: +45 24 22 19 69